A former head of medical at Sanofi-Aventis has sued the Australian branch of the pharmaceutical giant, claiming he was unfairly dismissed in a “‘sham redundancy” and faced discrimination because of his age and disabilities.
Mylan’s Australia unit is appealing decisions by the tax office to refuse deductions on interest paid under loans taken out by the pharmaceutical giant to help fund the $1.2 billion acquisition of generic drug maker Alphapharm almost 15 years ago.
Bayer has lost its bid to redact the names and contact details of potential group members from discovered documents in a Slater & Gordon-led class action over the drug maker’s Essure contraceptive device.
The maker of the popular Invisalign dental aligners has sued competitor SmileDirectClub for allegedly misleading consumers about the cost and efficacy of its direct-to-consumer teeth alignment kits.
Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to the Therapeutic Goods Administration, as it weighs a third patent infringement lawsuit to protect its multiple sclerosis drug against generic reproductions.
IVF company Virtus Health has withdrawn its offer to acquire rival Adora Fertility from Healius, citing the competition regulator’s opposition to the takeover.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
Group members in a class action over Bayer’s Essure contraceptives had “a ticking time bomb” in their bodies after being implanted with the devices, and all were at risk of developing injuries, a court has heard.
A judge was “mistaken” to find that AFT Pharmaceuticals’ ads for its painkiller Maxigesic were misleading, with the Full Federal Court ruling there was an adequate scientific foundation for the ads’ claims that the drug provided faster, better pain relief than paracetamol and ibuprofen alone.
An alternative therapies clinic in Victoria has been hit with $3 million in penalties for allegedly promoting “pseudo-scientific” treatments to vulnerable people with chronic illnesses in posts on social media and its website.